ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
 PMID: 15504868       2004       Antimicrobial agents and chemotherapy
Abstract: Similarly, when tested against a mutant virus fully resistant to inhibition by DAPD (K65R/Q151M), MPA and RBV reduced the EC(50) for DAPD to within twofold of that for the wild type.


  Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication.
 PMID: 15561833       2004       Antimicrobial agents and chemotherapy
Abstract: Lower levels of replication of the Gln145Met recombinant strain compared with those of both Gln151Met and wild-type recombinant strains were observed.
Abstract: This finding may explain the lower frequency of Gln145Met/Leu mutations observed compared with the frequencies of Gln151Met/Leu mutations and the insertion at position 69 in HAART-experienced patients.


  Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
 PMID: 15577635       2004       AIDS (London, England)
Abstract: The recognition of K65R correlated negatively with the presence of thymidine analogue mutations but positively with Q151M.


  Correlation of phenotypic zidovudine resistance with mutational patterns in the reverse transcriptase of human immunodeficiency virus type 1: interpretation of established mutations and characterization of new polymorphisms at codons 208, 211, and 214.
 PMID: 12499169       2003       Antimicrobial agents and chemotherapy
Abstract: Zidovudine resistance (ZDV-R) is associated with classic genotypic changes at codons 41, 67, 70, 210, 215, and 219 of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) gene as well as with the multinucleoside resistance (MNR) complexes (Q151M MNR complex; 6-bp insertion/A62V complex).


  Dioxolane guanosine 5'-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses.
 PMID: 12651859       2003       The Journal of biological chemistry
Abstract: HIV-1 with the reverse transcriptase mutations K65R, L74V, and/or Q151M were less sensitive to DXG, whereas the mutation K103N re-sensitized the virus to the inhibitory effect of DXG.


  K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
 PMID: 12741630       2003       Antiviral therapy
Abstract: One patient developed Q151M.


  HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
 PMID: 12790516       2003       Antiviral chemistry & chemotherapy
Abstract: D-d4FC is highly effective at inhibiting subsets of lamivudine- and zidovudine-resistant variants but, like other NRTIs, seems less potent against multi-NRTI-resistant viruses, particularly those carrying the Q151M complex of mutations.


  Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.
 PMID: 12819513       2003       AIDS (London, England)
Abstract: CONCLUSION: HIV-1(Q151M) probably develops through a poorly replicating HIV-1(Q151L); however, it is also possible that it occurs through two concurrent base changes.
Abstract: DESIGN AND METHODS: Propagation assays and competitive HIV-1 replication assays were used to evaluate the fitness of various infectious clones, including two putative intermediates (HIV-1(Q151K(AAG)) and HIV-(1Q151L(CTG))) for HIV-1(Q151M(ATG)), in terms of sensitivity to zidovudine and didanosine.
Abstract: HIV-1(Q151M) was less susceptible to drugs, while HIV-1(Q151L/M230I) was as sensitive as HIV-1(WT).